Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients; \>/= 18 years of age
Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
Relapsed or refractory multiple myeloma for which no effective standard therapy exists
One of the prior therapies must have included a proteosome inhibitor or an immunomodulatory drug
Measurable disease as defined by protocol
You may not be if
Prior use of monoclonal antibody within 4 weeks before Cycle 1, Day 1
Treatment with radiotherapy, thalidomide, lenalidomide, bortezomib, any chemotherapeutic agent, or treatment with any investigational anti-cancer agent within 2 weeks prior to Cycle 1, Day 1
Toxicities from any previous treatment must be resolved prior to Cycle 1, Day 1, except for neuropathy
Completion of autologous stem cell transplant within 100 days prior to Cycle 1, Day 1
Prior allogeneic stem cell transplant
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
Grade \> 1 peripheral neuropathy
Active infection at screening or any major episode of infection requiring treatment with IV antibiotics or hospitalization within 4 weeks prior to Cycle 1, Day 1
Positive for hepatitis B, hepatitis C or HIV infection
Pregnant or lactating women or women who intend to become pregnant within the period of time of this study
Clareo Health | A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
